We expect to continue growing revenue faster than the market in the coming year driven by continued strength in pet care, expansion of our diagnostics portfolio internationally as significant growth in both companion animal and livestock product sales for emerging markets, including China and Brazil.
Companion animal revenue grew 23% operationally, and livestock revenue declined 2% operationally.
Companion animal products led the way in terms of -- growth, growing 21% operationally, with livestock declining 6% on an operational basis in the quarter.
We grew revenue 15% operationally, which is once again above the anticipated growth rate for the animal health market, and these results were highlighted by 27% operational growth in our companion animal portfolio with 1% operational growth in livestock.
